Mesenchymal Stem Cells in the Treatment of Subjects With Advance COPD
Mesenchymal Stem Cells in the Treatment of Subjects With Advance Chronic Obstructive Pulmonary Disease (COPD)
Patients with advanced chronic obstructive pulmonary disease — characterized by a forced expiratory volume in 1 second (FEV1) value between 20% and 49% — who are already receiving maximal medical therapy are being enrolled in a pilot study. The study subjects receive MSCs from healthy young donors and are followed for one year. Jorge M. Mallea, M.D., Pulmonary Medicine at Mayo Clinic's campus in Jacksonville, Florida. is the principal investigator for this trial.
